You might think making important scientific discoveries would be accomplishment enough, but getting the word out to a global community of researchers is just as important—maybe even more so, as each publication spreads the knowledge and spurs future investigations. The CBTP lab researchers have been on a bit of a tear lately, publishing some of their most significant finds yet.
In spite of what may seem like esoteric titles, both of the following papers are key to the work done not only in our labs, but in labs around the world:
Malignant Astrocytic Tumor Progression Potentiated by JAK-Mediated Recruitment of Myeloid Cells
This paper from Dr. Greenfield’s team, fully five years in the making, details how a specific population of cells that are made in the bone marrow are recruited to the brain to facilitate brain tumor progression; more importantly it shows that inhibiting this process may act as a remote control of sorts to stop tumor progression. JAK inhibitors are compounds that are known to modulate immune responses in other disease states and interrupt signaling pathways involving proteins that have been implicated in cancer.
The paper is a true collaboration, written by Dr. Prajwal Rajappa of the CBTP and co-authored by Dr. David Lyden, professor of Pediatrics and Cell and Developmental Biology at Weill Cornell Medicine and pediatric neuro-oncologist at Memorial Sloan Kettering Cancer Center, and Dr. Jacqueline Bromberg, medical oncologist and researcher at Memorial Sloan Kettering Cancer Center. It was published in the June 2017 issue of the journal Clinical Cancer Research, but made available online for other researchers several months earlier.
Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models
This paper, by Dr. Souweidane’s team, describes a successful new way to measure and monitor tumor volume in patients with DIPG. DIPG is so infiltrative and amorphous that the tumor itself is nearly impossible to measure, which makes it especially difficult to monitor either its progression or its response to a treatment being tested. Developing a reliable means of measuring the volume of a DIPG tumor is a significant advance that will greatly aid in the assessment of potential new treatments.
The paper will appear in a future issue of Cancer Research and has been made available online in advance of publication.